Literature DB >> 12000688

The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment.

S O'Meara1, R Riemsma, L Shirran, L Mather, G ter Riet.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12000688     DOI： 10.3310/hta6060

Source DB:  PubMed          Journal:  Health Technol Assess        ISSN： 1366-5278            Impact factor:   4.014


× No keyword cloud information.
  6 in total

1.  Medications for obesity.

Authors:  Joel Lexchin; Ken Bassett; Pierre Biron; Peter Mansfield; Barbara Mintzes
Journal:  Can Fam Physician       Date:  2008-06       Impact factor: 3.275

2.  The value of medical and pharmaceutical interventions for reducing obesity.

Authors:  Pierre-Carl Michaud; Dana P Goldman; Darius N Lakdawalla; Yuhui Zheng; Adam H Gailey
Journal:  J Health Econ       Date:  2012-05-09       Impact factor: 3.883

Review 3.  Long-term pharmacotherapy for obesity and overweight.

Authors:  R Padwal; S K Li; D C W Lau
Journal:  Cochrane Database Syst Rev       Date:  2004

4.  Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

Authors:  Diana Rucker; Raj Padwal; Stephanie K Li; Cintia Curioni; David C W Lau
Journal:  BMJ       Date:  2007-11-15

Review 5.  A benefit-risk assessment of sibutramine in the management of obesity.

Authors:  Enzo Nisoli; Michele O Carruba
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis.

Authors:  M Gillett; H M Dallosso; S Dixon; A Brennan; M E Carey; M J Campbell; S Heller; K Khunti; T C Skinner; M J Davies
Journal:  BMJ       Date:  2010-08-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.